Alkem Laboratories vs Sutlej Textiles and Q3 FY26

AL

Alkem Laboratories

Q3 FY26 · Other

Alkem delivered a stable Q3 with total revenue of ₹3,737 crore (+10.7% YoY) and EBITDA margin of 22.2%. Domestic business grew 5.5% reported but ~10% on a normalized basis, driven by strong chronic portfolio and market share gains across six therapies. International sales surged 26.6% YoY to ₹1,216 crore. The highlight was the announcement of a 55% stake acquisition in Occlutech, a structural heart medtech company, for ~₹1,100 crore, with plans to scale revenue to ₹1,000 crore in 3-5 years and improve EBITDA margins from 4% to 25%. Management reiterated full-year guidance and bullish outlook. Key risk: MIP on penicillin derivatives could impact gross margins by 50-100 bps, though inventory and pricing actions may mitigate.

Guidance read

Domestic business to grow 100-150 bps above IPM: Management expects domestic business to continue growing 100-150 bps above IPM growth, with FY26 ending at ~10% growth. Occlutech EBITDA margin to reach 25% in 3-5 years: Occlutech's EBITDA margin is expected to improve from current ~4% to 25% in 3-5 years, driven by operating leverage and product mix. Occlutech revenue CAGR of 14% over 5 years: Occlutech is expected to grow at 14% CAGR over the next 5 years, reaching ~₹780 crore, excluding new products. Denosumab US entry by end of FY26: Denosumab US launch expected by end of FY26, pending FDA inspection and litigation resolution.

Risk read

Key risks include MIP on penicillin derivatives impacting gross margins — The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.; Occlutech integration and execution risk — Occlutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.; Denosumab litigation delay — US entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.; Trade generic business headwinds — Trade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth..

Promise ledger

Scorecard data is being built as historical quarters are processed.

Sutlej Textiles reported Q3 FY26 standalone revenue of INR 640 cr, down 2% YoY, but EBITDA surged over 200% YoY to INR 25 cr with margin expansion of 350 bps to 4%. PAT remained negative at INR -11 cr. The improvement was driven by cost optimization initiatives (30-40% of targeted savings achieved), product mix shift towards value-added yarns, and market diversification into Far East and Africa, reducing Bangladesh concentration. Home textiles order book provides visibility through Q1 FY27. Management expects Q4 to show continued sequential improvement, with full benefits of cost savings and renewable energy tie-ups (from Q1 FY27) flowing in over 2-3 quarters. Key risk: raw material price volatility, especially cotton, which rose 7-8% during the quarter and could pressure margins if not passed through.

Guidance read

Q4 FY26 sequential improvement in profitability: Management expects Q4 to be better than Q3, with continued momentum in operating margins. Cost savings target 40% achieved, full benefit in 2-3 quarters: Employee rationalization and process improvements have delivered ~40% of targeted annual savings; remaining benefits expected over next 2-3 quarters. Renewable energy benefits from Q1 FY27: Tied up for renewable energy; benefits expected to accrue from Q1 FY27, reducing energy cost (40% of yarn conversion cost). Home textiles order book visibility through Q1 FY27: Order book for home textiles provides visibility of ~120 days, i.e., through Q1 of next fiscal.

Risk read

Key risks include Raw material price volatility — Cotton prices increased 7-8% during the quarter; volatility in cotton and polyester prices can pressure margins if not passed through.; Bangladesh trade disruption — Bangladesh logistical issues have impacted yarn exports; management reduced exposure but uncertainty remains until elected government takes charge.; Global demand uncertainty and tariff risks — US-India trade situation and potential tariffs could affect export volumes; management notes real benefits may take two quarters to materialize.; Margin pressure in yarn business — Yarn segment EBITDA was only INR 1 cr despite contributing majority revenue; raw material inflation and competition keep margins under pressure..

Promise ledger

Scorecard data is being built as historical quarters are processed.